Literature DB >> 11105782

Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe lectin.

H O Pae1, W G Seo, G S Oh, M K Shin, H S Lee, H S Lee, S B Kim, H T Chung.   

Abstract

Mistletoe lectins (MLs) constitute the active principle in extract preparations from mistletoe, commonly used as immunomodulator in adjuvant tumor therapy. MLs, classified as type II ribosome inactivating proteins, inhibit protein synthesis. Inhibitors of protein synthesis may modify cancer cell response to tumor necrosis factor-alpha (TNF). In the present study, we have hypothesized that the anticancer efficacy of TNF may be potentiated by MLs. In deed, simultaneous treatment of human cervix carcinoma HeLa or breast carcinoma MCF-7 cells with MLs isolated from European or Korean mistletoe rendered them more sensitive to induction of apoptosis by TNF. The mechanism by which MLs amplify the effect of TNF may involve suppression of the survival protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11105782     DOI: 10.3109/08923970009016433

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  4 in total

1.  Ligatoxin B, a new cytotoxic protein with a novel helix-turn-helix DNA-binding domain from the mistletoe Phoradendron liga.

Authors:  Shi-Sheng Li; Joachim Gullbo; Petra Lindholm; Rolf Larsson; Eva Thunberg; Gunnar Samuelsson; Lars Bohlin; Per Claeson
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

Review 2.  Preclinical and clinical effects of mistletoe against breast cancer.

Authors:  Mohsen Marvibaigi; Eko Supriyanto; Neda Amini; Fadzilah Adibah Abdul Majid; Saravana Kumar Jaganathan
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

Review 3.  Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research.

Authors:  Gunver S Kienle; Anja Glockmann; Michael Schink; Helmut Kiene
Journal:  J Exp Clin Cancer Res       Date:  2009-06-11

4.  NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors.

Authors:  Patrick J Mansky; Dawn B Wallerstedt; Timothy S Sannes; Jamie Stagl; Laura Lee Johnson; Marc R Blackman; Jean L Grem; Sandra M Swain; Brian P Monahan
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-27       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.